Suppr超能文献

抗真菌联合用药对模拟念珠菌性心内膜赘生物的活性及超微结构影响

Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations.

作者信息

Pai Manjunath P, Samples Marie L, Mercier Renee-Claude, Spilde Michael N

机构信息

College of Pharmacy, MSC09 5360, 1 University of New Mexico, Albuquerque, NM 87131, USA.

出版信息

Antimicrob Agents Chemother. 2008 Jul;52(7):2367-76. doi: 10.1128/AAC.01557-07. Epub 2008 Apr 21.

Abstract

In vitro pharmacodynamic model (PDM) simulation of serum antifungal concentrations may predict the value of combination antifungal regimens against Candida sp. endocarditis. We investigated the effects of combinations of flucytosine (5FC), micafungin (Mica), and voriconazole (Vor) against Candida-infected human platelet-fibrin clots, used as simulated endocardial vegetations (SEVs). Single clinical bloodstream isolates of Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis were used. All four isolates were susceptible to 5FC, while C. glabrata was resistant to Vor and C. tropicalis had a paradoxical resistance phenotype to Mica. The SEVs were prepared with an initial inoculum of 1 x 10(6) CFU/g of SEV and added to a PDM, which utilized yeast nitrogen broth-2% glucose and incubation at 35 degrees C and simulated antifungal pharmacokinetic profiles. Fungal densities in the SEVs were determined in quadruplicate over 72 h. Scanning electron microscopy (SEM) was used to evaluate treatment and control SEVs. Vor was the least active single agent against all Candida spp. except for C. parapsilosis, where it was comparable to Mica. In contrast, 5FC was the most active against all Candida spp. except for C. tropicalis, where it was comparable to Mica. The combination of 5FC plus Vor was superior to either agent alone against C. parapsilosis. The combination of Vor plus Mica was inferior to the use of Mica alone against C. tropicalis. The triple combination of 5FC plus Vor plus Mica was no better than single or dual agents against any of the Candida spp. The ultrastructural features of infected SEVs were unique for each Candida sp., with C. parapsilosis in particular manifesting friable biofilm clusters. In general, 5FC and Mica were superior in their rates and extents of fungal burden reduction compared to Vor against Candida-infected SEVs. Evaluation of 5FC and Mica in animal models of Candida endocarditis is warranted.

摘要

血清抗真菌浓度的体外药效学模型(PDM)模拟可预测联合抗真菌方案治疗念珠菌性心内膜炎的价值。我们研究了氟胞嘧啶(5FC)、米卡芬净(Mica)和伏立康唑(Vor)联合用药对念珠菌感染的人血小板 - 纤维蛋白凝块(用作模拟心内膜赘生物(SEV))的影响。使用了白色念珠菌、光滑念珠菌、近平滑念珠菌和热带念珠菌的单株临床血流分离株。所有这四种分离株对5FC敏感,而光滑念珠菌对Vor耐药,热带念珠菌对Mica表现出矛盾的耐药表型。制备初始接种量为1×10(6) CFU/g SEV的SEV,并将其添加到PDM中,该模型使用酵母氮肉汤 - 2%葡萄糖,在35℃下孵育并模拟抗真菌药代动力学特征。在72小时内对SEV中的真菌密度进行四次测定。使用扫描电子显微镜(SEM)评估治疗组和对照组的SEV。除近平滑念珠菌外,Vor对所有念珠菌属的活性最低,在近平滑念珠菌中其活性与Mica相当。相比之下,5FC对除热带念珠菌外的所有念珠菌属活性最高,在热带念珠菌中其活性与Mica相当。5FC加Vor的联合用药对近平滑念珠菌的效果优于单独使用任何一种药物。Vor加Mica的联合用药对热带念珠菌的效果不如单独使用Mica。5FC加Vor加Mica的三联用药对任何念珠菌属的效果都不比单药或双药更好。感染SEV的超微结构特征因每种念珠菌属而异,特别是近平滑念珠菌表现出易碎的生物膜簇。总体而言,与Vor相比,5FC和Mica在降低念珠菌感染SEV的真菌负荷的速率和程度方面更具优势。有必要在念珠菌性心内膜炎动物模型中评估5FC和Mica。

相似文献

1
Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations.
Antimicrob Agents Chemother. 2008 Jul;52(7):2367-76. doi: 10.1128/AAC.01557-07. Epub 2008 Apr 21.
2
Antifungal combinations against simulated Candida albicans endocardial vegetations.
Antimicrob Agents Chemother. 2009 Jun;53(6):2629-31. doi: 10.1128/AAC.01026-08. Epub 2009 Mar 23.
3
Antifungal susceptibility of Candida isolates at one institution.
Med Mycol J. 2014;55(1):E1-7. doi: 10.3314/mmj.55.e1.
4
[Antifungal susceptibility among the isolates of yeast from the University Hospital of the Ryukyus].
Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi. 2005;16(2):127-33.
6
In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.
Int J Antimicrob Agents. 2006 Feb;27(2):174-7. doi: 10.1016/j.ijantimicag.2005.10.014. Epub 2006 Jan 18.
8
Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):592-5. doi: 10.1007/s10096-005-0005-y.

引用本文的文献

1
Candida endocarditis: Update on management considerations.
World J Cardiol. 2023 Oct 26;15(10):469-478. doi: 10.4330/wjc.v15.i10.469.
2
Antifungal Combinations against Species: From Bench to Bedside.
J Fungi (Basel). 2022 Oct 13;8(10):1077. doi: 10.3390/jof8101077.
3
The future of biofilm research - Report on the '2019 Biofilm Bash'.
Biofilm. 2019 Dec 24;2:100012. doi: 10.1016/j.bioflm.2019.100012. eCollection 2020 Dec.
4
Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.
Mycopathologia. 2013 Feb;175(1-2):129-34. doi: 10.1007/s11046-012-9591-2. Epub 2012 Oct 17.
6
Contribution of serotype and genetic background to biofilm formation by Streptococcus pneumoniae.
Eur J Clin Microbiol Infect Dis. 2011 Jan;30(1):97-102. doi: 10.1007/s10096-010-1060-6. Epub 2010 Sep 16.
7
Antifungal combinations against simulated Candida albicans endocardial vegetations.
Antimicrob Agents Chemother. 2009 Jun;53(6):2629-31. doi: 10.1128/AAC.01026-08. Epub 2009 Mar 23.

本文引用的文献

1
Requirement for Candida albicans Sun41 in biofilm formation and virulence.
Eukaryot Cell. 2007 Nov;6(11):2046-55. doi: 10.1128/EC.00314-07. Epub 2007 Sep 14.
2
Candida parapsilosis endocarditis: a comparative review of the literature.
Eur J Clin Microbiol Infect Dis. 2007 Dec;26(12):915-26. doi: 10.1007/s10096-007-0386-1.
3
Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals.
Antimicrob Agents Chemother. 2007 Apr;51(4):1520-3. doi: 10.1128/AAC.01141-06. Epub 2007 Feb 5.
4
Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method.
Diagn Microbiol Infect Dis. 2007 May;58(1):129-32. doi: 10.1016/j.diagmicrobio.2006.10.017. Epub 2007 Jan 19.
5
The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.
Pharmacology. 2006;78(4):161-77. doi: 10.1159/000096348. Epub 2006 Oct 17.
6
Invasive candidiasis.
Infect Dis Clin North Am. 2006 Sep;20(3):485-506. doi: 10.1016/j.idc.2006.07.004.
7
Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis.
Eur J Drug Metab Pharmacokinet. 2006 Apr-Jun;31(2):123-8. doi: 10.1007/BF03191129.
9
Pharmacokinetic/pharmacodynamic profile of voriconazole.
Clin Pharmacokinet. 2006;45(7):649-63. doi: 10.2165/00003088-200645070-00002.
10
Biofilms and their role in the resistance of pathogenic Candida to antifungal agents.
Curr Drug Targets. 2006 Apr;7(4):465-70. doi: 10.2174/138945006776359458.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验